

Assessment of Behavioural and Psychological Symptoms Associated with Dementia

David Conn, Lilian Thorpe

ABSTRACT: Neuropsychiatric symptoms (mood, psychotic, and behavioural) are very common in dementia and do not necessarily correlate well with other measures of cognition. However, these symptoms are of great importance, as they are a major source of excess disability, patient distress and caregiver burden and have great impact on the level of care required, and the associated costs. This paper is a review of the most useful outcome measures for behaviour and mood symptoms. Investigators who require a comprehensive instrument to measure neuropsychiatric symptoms in studies of patients with dementia should consider using the Neuropsychiatric Inventory (NPI), the Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD-BRSD) or, possibly, the Behavioral Pathology in Alzheimer's Disease Scale (BEHAVE-AD). The Cornell Scale for Depression in Dementia and the Dementia Mood Assessment Scale (DMAS) are recommended for evaluating depressive symptoms and the Cohen-Mansfield Agitation Inventory (CMAI) is very useful for evaluating the full range of agitation symptoms.

RÉSUMÉ: Évaluation des symptômes comportementaux et psychologiques associés à la démence. Les symptômes neuropsychiatriques (dysthymiques, psychotiques et comportementaux) sont très fréquents dans la démence et leur corrélation aux autres mesures de la cognition n'est pas toujours bonne. Cependant, ces symptômes sont très importants parce qu'ils sont une source majeure d'invalidité supplémentaire et de détresse pour le patient, un fardeau pour les soignants et parce qu'ils ont un impact considérable sur le niveau de soins requis et les coûts qui y sont associés. Cet article revoit les mesures d'impact les plus utiles pour l'évaluation des symptômes comportementaux et thymiques. Les chercheurs qui ont besoin d'instruments détaillés pour évaluer les symptômes neuropsychiatriques au cours des études portant sur des patients déments devraient faire appel au Neuropsychiatric Inventory (NPI), au Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD-BRSD), ou encore au Behavioral Pathology in Alzheimer's Disease Scale (BEHAVE-AD). Le Cornell Scale for Depression in Dementia et le Dementia Mood Assessment Scale (DMAS) sont recommandés pour l'évaluation des symptômes dépressifs et le Cohen-Mansfield Agitation Inventory (CMAI) est très utile pour l'évaluation de toute la gamme des symptômes d'agitation.

Can. J. Neurol. Sci. 2007; 34: Suppl. 1 - S67-71

Neuropsychiatric symptoms (mood, psychotic, and behavioural) are very common in dementia and do not necessarily correlate well with other measures of cognitive functioning.¹ However, these symptoms are of great importance, as they are a major source of excess disability, patient distress, caregiver burden and contribute greatly to the level of care required, and associated costs. It is therefore important that the assessment of neuropsychiatric symptoms is included as a core component in trials of antidementia therapies. Numerous instruments are available for assessing neuropsychiatric symptoms in patients suffering from dementia. It is likely that the lack of a consistent approach to the measurement of these problems contributes to the variability of rates reported in observational studies.²

Antidementia therapies may not have a uniform impact on all areas, and it is conceivable that an improvement in one domain

is associated with worsening in another. For example, there is evidence from some trials that cholinesterase inhibitors may prevent the emergence of neuropsychiatric symptoms in patients with dementia and may also have direct benefits for certain behaviours, such as apathy and psychotic symptoms. On the other hand, some independently designed studies have shown no significant improvement in various neuropsychiatric symptoms.³

From the Departments of Psychiatry, Baycrest Centre for Geriatric Care, University of Toronto, Toronto, Ontario; Saskatoon City hospital, University of Saskatchewan, Saskatchewan, Canada.

RECEIVED MARCH 24, 2006. ACCEPTED IN FINAL FORM SEPTEMBER 2, 2006.

Reprint requests to: David Conn, Department of Psychiatry, Baycrest Centre for Geriatric Care, Room 4C91, 3560 Bathurst Street, Toronto, Ontario, M6A 2E1, Canada.

In addition, worsening in some domains, such as sleep, may occur. It is important to note that trials of antidementia drugs have almost exclusively measured behaviour as a secondary outcome measure, with post-hoc analyses of the behavioural domains. Aggregate measures, such as global outcome scales, may be less useful than measures addressing specific clinical domains. This is also supported by population-based phenomenological surveys, such as the Cache County Study, that have explored different symptom clusters. Authors reporting on this large population study of adults over 65 ($n=5,092$) suggested that symptoms clustered into three main syndromes: an affective syndrome, a psychotic syndrome, and other neuropsychiatric disturbances.⁴ Further work has also gone into defining diagnostic criteria for such syndromes, such as that by Olin et al⁵ who described diagnostic criteria for depression of Alzheimer's disease, and by Schneider & Dagerman⁶ who described clustering of symptoms to suggest the validity of a syndrome of psychosis of Alzheimer's disease.

Thus, instruments that assess neuropsychiatric symptoms in dementia include those that are designed to identify a variety of common neuropsychiatric symptoms not necessarily part of another comorbid diagnostic category, as well as those that are designed to identify specific syndromes or comorbid diagnoses, such as depression or psychosis. Although it is tempting to include instruments detailed enough to make valid diagnoses of these comorbid disorders, this increases the complexity and length of the dementia trial protocol, so this is not usually done unless the trial is geared particularly to this problem.

There are a number of important issues related to the interpretation and evaluation of neuropsychiatric symptoms.² One of the most significant issues relates to the source of the information. Patients with significant cognitive impairment are likely to be somewhat unreliable historians. This is most notable for data requiring intact memory (as required in the documentation of previous behaviours), but also for data requiring relatively intact and sophisticated comprehension and communication. Therefore, the ideal respondent, especially in moderate to late dementia trials, is not the patient him/herself but a close contact with intact cognitive functioning. This is usually a family caregiver for community-dwelling patients, although he/she may lack the skills needed for sophisticated observation. In addition, caregivers' reports may be influenced by their own emotional states or their relationship with the patient. Nevertheless, other non-family informants may be of limited helpfulness because of fewer and shorter periods of available observation, such as, in the case of data provision by visiting home care aides or nurses.

There has been debate with regard to the usefulness of measuring frequency versus severity. Reisberg et al⁷ pointed out that because the time spent by caregiver informants with patients varies greatly, frequency may be insensitive compared to the magnitude of the disturbance. It is also important to note that magnitude may be of greater clinical relevance. Tariot et al⁸ argue that frequency is preferable, as severity is more difficult to anchor. Some scales rely on a summation of frequency multiplied by severity. A further complication is that neuropsychiatric symptoms fluctuate, are not present in all patients, and do not necessarily progress at a uniform rate. Many scales have been described in the literature, but, for this review,

the choice of scales is primarily based on neuropsychiatric symptom ratings commonly used in clinical trials. The Table lists the number of items, range of scores for each item and maximum score for each scale described in the paper.

MOOD SCALES

Mood symptoms have an important and heterogeneous relationship to dementia. They may present as isolated symptoms and either predate the recognition of dementia, or appear in the course of an established dementing process. Mood symptoms may also be more pervasive and be part of a subsyndromal, yet clinically significant, depressive disorder. Alternatively, symptoms may be part of a major depressive disorder. Symptoms of mood disorders have considerable overlap with core symptoms of dementia, such as apathy, sleep disturbance, weight loss, and emotional dyscontrol. Therefore, instruments used to assess mood changes in dementia must avoid either over or under identification of mood syndromes. Self-reports are less reliable as dementia progresses, making the integration of caregiver information most important.

Many global dementia-rating instruments have included some mood symptoms as items contributing to the total score; however, mood items within these instruments are often scored in such a way that it is difficult to assess their magnitude, clinical importance, or progression, or to make a judgment of whether the mood symptom is an isolated symptom of dementia or part of a core mood disorder. On the other hand, more detailed mood instruments developed to describe and quantify mood disorders in the non-demented population [Hamilton Depression Rating Scale (1960); Montgomery-Asberg Depression Rating Scale (1979); Zung Scale (1965); Beck Depression Inventory (1961); Geriatric Depression Scale (1983)] are not valid in later stages of dementia when language and comprehension have declined significantly.⁹⁻¹⁴ Therefore, in studies where the assessment of mood in dementia is of major importance, it is best to use an instrument that has been developed specifically for this purpose. Two such instruments are the Dementia Mood Assessment Scale and the Cornell Scale for Depression in Dementia.^{15,16} Of course, even these are screening tools, and the gold-standard diagnosis of depressive disorder in dementia is still a clinical one. The process is complex, and requires a high level of experience, knowledge, acumen, and, usually, informed second-party information.

The Cornell Scale for Depression in Dementia

The Cornell Scale is a well known, mostly caregiver-rated scale that is particularly suited to differentiating between cognitive and mood symptoms, and is sensitive to treatment effects over a wide range of depression severity.¹⁶ The scale has 19 items that are based on the week prior to the interview and which are rated as absent, mild or intermittent, and severe. Symptoms are clustered into five main categories: mood related signs, behavioural disturbance, physical signs, cyclic functions, and ideational disturbance. Published inter-rater reliability kappa is 0.67, internal consistency is reasonable (0.84), and it has been found to be valid, based on comparison with the Hamilton Depression Rating Scale and Research Diagnostic Criteria.¹⁷ The time required for this instrument is about 20 minutes with the caregiver and 10 minutes with the patient.¹⁸

Table: Scoring of Scales

	Number of items	Score for each item	Maximum Score ^c
1. NPI	12	0-12	144
2. CERAD-BRSD	46	0-4	148 ^a
3. BEHAVE-AD	25	0-3	75
4. ADAS-Noncog	10	0-5	50
5. BPRS	16	1-7	112
6. Cornell Scale	19	0-2	38
7. DMAS	24	0-6	102 ^b
8. CMAI-long form	29	1-7	203

^a 37 items are rated 0-4. 8 items are scored yes/no and one asks for additional behaviours. ^b 17 items rate mood. ^c Higher scores indicate greater psychopathology on all scales.

Dementia Mood Assessment Scale

The Dementia Mood Assessment Scale (DMAS) was developed with an inpatient population by Sunderland and Minichello and was modeled on the Hamilton Depression Scale (HDS).^{15,19} Items were removed from the HDS that were felt to be subjective and vulnerable to error in demented patients. The final version of the DMAS has 24 items, with the first 17 items designed to assess the severity of depression and the last 7 items designed to measure the severity of dementia. Trained interviewers score items with input from nursing staff and/or family caregivers. Validity was found to be good, as measured against the Geriatric Depression Scale and the Montgomery-Asberg Depression Rating Scale. Inter-rater reliability and intra-class correlations were high. As this scale was developed with inpatients, and less information is available on it, it is used less often than the Cornell Scale.

GLOBAL BEHAVIOUR SCALES

Neuropsychiatric Inventory (NPI)

This scale was published in 1994, and measures a wide range of neuropsychiatric disturbances.²⁰ The initial scale evaluated ten items, which included delusions, hallucinations, dysphoria, anxiety, agitation, euphoria, apathy, irritability, disinhibition, and aberrant motor behaviour. Two items were later added (i.e., nighttime behaviour and changes in appetite and eating behaviours). It is based on a structured interview conducted by a clinician with a caregiver. Screening questions are asked, initially, and followed-up, if necessary, by subquestions. The caregiver rates the frequency on a 4-point scale and severity on a 3-point scale. On a test-retest reliability study, correlation coefficients were .79 for overall frequency and .86 for overall severity.²¹ Studies have reported good inter-rater reliability.^{20,22} There is high internal consistency, and criterion (concurrent) validity was also assessed by correlating questions measuring similar behaviours on the NPI and the BEHAVE-AD.²¹ Most item pairs showed good to moderate correlations. Several studies

have evaluated the nursing home version of the NPI. A recent Canadian study suggested that five factors accounted for 63% of the variance.²³ These factors were agitation, mood, psychosis, sleep/motor activity, and elevated behaviour. Convergent and discriminate validity of the five factors by correlating them with other behavioural measures was considered satisfactory. A study by Iverson et al. looked at measuring change using the nursing home version of the NPI.²⁴ Estimates of reliable change on the individual subscales range from 1.9 points on the euphoria/elation subscale to 5.13 points on the anxiety subscale. A change in the total score of plus or minus 22 points was required to exceed the possible range of measurement error at the 0.8 confidence interval.²⁴

A number of versions of the NPI have been translated into other languages and these have also been studied. These studies have generally supported the use of the NPI and include translations into Greek;²⁵ Spanish (NPI-Q);²⁶ Dutch;^{27,28} Korean;²⁹ and Chinese.³⁰

A brief version of the NPI (NPI-Q) that is intended for use in routine clinical practice has also been studied.³¹ It has been cross-validated with the NPI and is considered to be a brief, reliable, informant-based assessment of neuropsychiatric symptoms and associated caregiver distress. A review by Forester and Oxman recommends the use of the NPI-Q as being the most appropriate for use in primary care.³²

A review by Perrault of outcome measurement instruments in Alzheimer's disease suggested that more work was required to provide evidence of the NPIs responsiveness to change.² Concerns were also raised about the gaps in score distribution (i.e., there are no multiples of 5, 7, and 11).

CERAD-BRSD

The Behaviour Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease is composed of 46 questions, 37 of which are rated on a 5-point scale.³³ The ratings measure behavioural symptoms over the previous month. Items were taken from previously existing scales and were designed to be administered to caregivers. The BRSD has six subscales: depressive symptoms, psychotic symptoms, inertia, vegetative symptoms, irritability/aggression, and behavioural dysregulation. A study comparing the BRSD with the CMAI, the Revised Memory and Behavioural Problems Checklist (RMBPC), and the Agitated Behaviour and Dementia Scale (ABD), as compared to the Clinical Global Impression of Change (CGIC), was carried out by Weiner.³⁴ The four specific behavioural/agitation subscales had excellent cross-sectional and longitudinal correlations with each other, suggesting high validity. Changes on the CGIC did not correlate well with change scores on the other instruments.³⁴ Test/retest reliability was moderately high and inter-rater reliability was high on individual items.^{8,35} The authors did suggest that estimates of reliability may have been inflated due to the lack of inclusion of subjects with extensive psychopathology. Construct validity was supported by the high correlation ($r=.76$) between the total BRSD and total CMAI scores in assessments of 206 patients with Alzheimer's disease.³⁶ Validity was also supported from a factor analysis study.³⁷ Perrault et al suggested that there was enough preliminary evidence on the reliability and validity of the BRSD to suggest that it can be used provisionally as an outcome measure in Alzheimer's disease drug trials.²

Behavioural Pathology in AD Scale (BEHAVE-AD)

This scale is one of the earliest rating scales to be used in the dementia field. The items were taken from a chart review of 57 outpatients with Alzheimer's disease.³⁸ It includes the assessment of symptoms and a global rating of caregiver distress. Twenty-five behaviours in seven clusters are rated. These areas include paranoid and delusional ideation, hallucinations, activity disturbances, aggressiveness, diurnal rhythm disturbances, affective disturbance, and anxieties and phobias. Caregivers rate the symptoms over the preceding two weeks on a 0 to 3 scale. The caregiver also determines a global assessment of caregiver distress on a scale of 0 to 3. The BEHAVE-AD is considered to be a valid and reliable scale, which takes approximately 20 minutes to administer.³⁹ It assesses psychosis as well as agitation, aggression, and affective changes. The BEHAVE-AD has been used in recent pharmacological studies of the effectiveness of treatments for BPSD. A variation of the BEHAVE-AD, termed the E-BEHAVE-AD, which relies on the direct observation of behavioural symptoms, has also been developed.⁴⁰ There has also been the addition of a frequency-weighted score to the BEHAVE-AD, which includes ratings of severity and frequency. This scale (BEHAVE-AD-FW) has been studied with results indicating that the frequency-weighted component is a reliable addition to the original scale.⁴¹ Finally, a Chinese version of the BEHAVE-AD has been studied, and the findings suggest that the instrument is a valid tool for behavioural disturbances in patients with AD.⁴²

Other Instruments

The ADAS-noncog is a subscale of the ADAS, which measures behaviour and mood symptoms.^{43,44} It rates patients on 10 items grouped into six clusters. The assessment is based on clinicians' observations, plus an interview with a caregiver. Perrault et al note that the validity of the ADAS-noncog in Alzheimer's disease drug trials is questionable.² Three of its items are outside of the domain of behaviour and mood (tremors, concentration/distractibility, and appetite changes). In addition, aggressiveness and anxiety are not included in this scale. At this time, the ADAS-noncog is not considered to be one of the instruments of choice.

Despite the fact that the Brief Psychiatric Rating Scale (BPRS) was originally designed to assess drug treatment effects in a general adult psychiatric population, it has also been used in studies of the elderly.^{45,46} There are 18 items, each of which is rated on a scale of 1 to 7 according to severity. Schneider et al note that the BPRS has proven to be very useful and sensitive to changes in many AD clinical trials;⁶ however, Perrault et al believe that the scale has important shortcomings in terms of content validity and report that it includes items that are irrelevant, unspecific, or confounded by cognition.² They also note that direct patient interview may lead to inadequate assessment and conclude that the BPRS has limited utility as an outcome measurement scale in Alzheimer's disease drug trials.

Scale for Observable Behaviour (Agitation)

Cohen-Mansfield Agitation Inventory (CMAI)

The Cohen-Mansfield Agitation Inventory (CMAI) is an empirical scale that measures only observable behaviours, and

does not consider patients' mood or thought content. It was developed in nursing homes for nursing home use^{47,48} and is subject to floor effects in community dwelling patients with mild degrees of behavioural disturbance. The CMAI uses a 7-point scale to assess the frequency of 29 behaviours commonly seen in nursing home residents. Behaviours are characterized in four clusters: verbally aggressive (e.g., directed at a person or object), verbally nonaggressive (not directed at a specific object or person), physically aggressive (directed), and physically nonaggressive (undirected), but the total score is most commonly used to quantify behavioural disturbance. The scale is filled out by professional caregivers who are usually nurses or nursing assistants. The staff needs to be trained prior to using the instrument. The scale is observational and can be administered using either a short or long form. The CMAI takes an average of 20 minutes to complete. The instrument has been found to be reliable and valid.^{49,50} Additional versions of the instrument have been developed, including a Community form (CMAI-C), a 38-item questionnaire for interviews with caregivers or relatives, and a short form (14 items).

CONCLUSION

Investigators who require a comprehensive instrument to measure neuropsychiatric symptoms in studies of patients with dementia should consider using the NPI, the CERAD-BRSD, or, possibly, the BEHAVE-AD. The NPI is currently the most frequently used scale. For investigators who are particularly focusing on mood, the Cornell Scale for Depression in Dementia and the DMAS are appropriate. The CMAI is particularly useful for personnel with limited training, as it measures only observable behaviours and not phenomenology that would require a professionally trained examiner to elicit.

REFERENCES

1. Spalletta G, Baldinetti F, Buccione I, Fadda L, Perri R, Scalmana S, et al. Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer's disease. *J Neurol*. 2004; 251(6): 688-95.
2. Perrault A, Oremus M, Demers L, Vida S, Wolfson C. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of behaviour and mood scales. *J Geriatr Psychiatry Neurol*. 2000; 13(4): 181-96.
3. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. *Lancet*. 2004; 363(9427): 2105-15.
4. Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. *Int J Geriatr Psychiatry*. 2001; 16(11): 1043-53.
5. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, et al. Provisional diagnostic criteria for depression of Alzheimer's disease. *Am J Geriatr Psychiatry*. 2002; 10(2): 125-8.
6. Schneider LS, Dagerman KS. Psychosis of Alzheimer's disease: clinical characteristics and history. *J Psychiatr Res*. 2004; 38(1): 105-11.
7. Reisberg B, Auer SR, Monteiro I, Boksay I, Sclan SG. Behavioural disturbances of dementia: an overview of phenomenology and methodologic concerns. *Int Psychogeriatr*. 1996; 8 Suppl 2: 169-82.
8. Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, et al. The Behaviour Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease: The Behavioral Pathology Committee of the Consortium to

- Establish a Registry for Alzheimer's Disease. *Am J Psychiatry*. 1995; 152: 1349-59.
9. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatr*. 1960; 23: 56-62.
10. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry*. 1979; 134: 382-9.
11. Zung WWK. A self-rating depression scale. *Arch Gen Psychiatry*. 1965; 12: 63-70.
12. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry*. 1961; 4: 53-63.
13. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer's disease. Rationale and background. *Am J Geriatr Psychiatry*. 2002; 10(2): 129-41.
14. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. *J Psychiatr Res*. 1982-83; 17(1): 37-49.
15. Sunderland T, Minichiello M. Dementia Mood Assessment Scale. *Int Psychogeriatr*. 1996; 8 Suppl 3: 329-31.
16. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. *Biol Psychiatry*. 1988; 23: 271-84.
17. Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. *Arch Gen Psychiatry*. 1972; 26(1): 57-63.
18. Burns A, Lawlor B, Craig S. Cornell Scale for depression in dementia. In: *Assessment Scales in Old Age Psychiatry*. London: Martin Dunitz; 1999.
19. Sunderland T, Alterman IS, Yount D, Hill JL, Tariot PN, Newhouse PA, et al. A new scale for the assessment of depressed mood in demented patients. *Am J Psychiatry*. 1988; 145(8): 955-9.
20. Cummings JL, Mega MS, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment in psychopathology in dementia. *Neurology*. 1994; 44: 2308-14.
21. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. *Neurology*. 1997; 48 Suppl 6: S10-16.
22. Frisoni GB, Rozzini L, Gozzetti A, Binetti G, Zanetti O, Bianchetti A, et al. Behavioral syndromes in Alzheimer's disease: description and correlates. *Dement Geriatr Cogn Disord*. 1999; 10: 130-8.
23. Lange RT, Hopp GA, Kang N. Psychometric properties and factor structure of the Neuropsychiatric Inventory Nursing Home version in an elderly neuropsychiatric population. *Int J Geriatr Psychiatry*. 2004; 19(5): 440-8.
24. Iverson GL, Hopp GA, DeWolfe K, Solomons K. Measuring change in psychiatric symptoms using the Neuropsychiatric Inventory: Nursing Home version. *Int J Geriatr Psychiatry*. 2002; 17(5): 438-43.
25. Politis AM, Mayer LS, Passa M, Maillis A, Lyketsos CG. Validity and reliability of the newly translated Hellenic Neuropsychiatric Inventory (H-NPI) applied to Greek outpatients with Alzheimer's disease: a study of disturbing behaviours among referrals to a memory clinic. *Int J Geriatr Psychiatry*. 2004; 19(3): 203-8.
26. Boada M, Cejudo JC, Tarraga L, Lopez OL, Kaufer D. Neuropsychiatric inventory questionnaire (NPI-Q): Spanish validation of an abridged form of the Neuropsychiatric Inventory (NPI). *Neurologia*. 2002; 17(6): 317-23.
27. de Jonghe JF, Kat MG, Kalisvaart CJ, Boelaarts L. Neuropsychiatric Inventory Questionnaire (NPI-Q): a validity study of the Dutch form. *Tijdschr Gerontol Geriatr*. 2003; 34(2): 74-7.
28. Kat MG, de Jonghe JF, Aalten P, Kalisvaart CJ, Dros RM, Verhey FR. Neuropsychiatric symptoms of dementia: psychometric aspects of the Dutch Neuropsychiatric Inventory (NPI). *Tijdschr Gerontol Geriatr*. 2002; 33(4): 150-5.
29. Choi SH, Na DL, Kwon HM, Yoon SJ, Jeong JH, Ha CK. The Korean version of the neuropsychiatric inventory: a scoring tool for neuropsychiatric disturbance in dementia patients. *J Korean Med Sci*. 2000; 15(6): 609-15.
30. Leung VP, Lam LC, Chiu HF, Cummings JL, Chen QL. Validation study of the Chinese version of the neuropsychiatric inventory (CNPI). *Int J Geriatr Psychiatry*. 2001; 16(8): 789-93.
31. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. *J Neuropsychiatry Clin Neurosci*. 2000; 12(2): 233-9.
32. Forester BP, Oxman TE. Measures to Assess the Noncognitive Symptoms of Dementia in the Primary Care Setting. *Prim Care Companion J Clin Psychiatry*. 2003; 5(4): 158-63.
33. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. Consortium to Establish a Registry for Alzheimer's Disease (CERAD): clinical and neuropsychological assessment of Alzheimer's disease. *Psychopharmacol Bull*. 1988; 24: 641-52.
34. Weiner MF, Tractenberg R, Teri L, Logsdon R, Thomas RG, Gamst A, et al. Quantifying behavioural disturbances in Alzheimer's disease patients. *J Psychiatr Res*. 2000; 34(2): 163-7.
35. Patterson MB, Mack JL, Mackell JA, Thomas R, Tariot P, Weiner M, et al. A longitudinal study of behavioural pathology across five levels of dementia severity in Alzheimer's disease: the CERAD Behaviour Rating Scale for Dementia. *Alzheimer Dis Assoc Disord*. 1997; 11 Suppl 2: S40-4.
36. Weiner MF, Koss E, Patterson M, Jin S, Teri L, Thomas R, et al. A comparison of the Cohen-Mansfield agitation inventory with the CERAD behavioural rating scale for dementia in community-dwelling persons with Alzheimer's disease. *J Psychiatr Res*. 1998; 32: 347-51.
37. Mack JL, Patterson MB, Tariot PN. Behaviour rating scale for dementia: development of test scales and presentation of data for 555 individuals with Alzheimer's disease. *J Geriatr Psychiatry Neurol*. 1999; 12: 211-13.
38. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioural symptoms in Alzheimer's disease: phenomenology and treatment. *J Clin Psychiatry*. 1987; 48(Suppl): 9-15.
39. Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, et al. A multicentre evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. *Alzheimer Dis Assoc Disord*. 1997; 11 Suppl 2: S1-12.
40. Auer SR, Montiero IM, Reisberg B. The Empirical Behavioral Pathology in Alzheimer's Disease (E-BEHAVE-AD) Rating Scale. *Int Psychogeriatr*. 1996; 8(2): 247-66.
41. Monteiro IM, Boksay I, Auer SR, Torossian C, Ferris SH, Reisberg B. Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer's Disease Rating Scale: the BEHAVE-AD-FW: methodology and reliability. *Eur Psychiatry*. 2001; 16 Suppl 1: 5s-24s.
42. Lam LC, Tang WK, Leung V, Chiu HF. Behavioral profile of Alzheimer's disease in Chinese Elderly: a validation study of the Chinese version of the Alzheimer's disease behavioural pathology rating scale. *Int J Geriatr Psychiatry*. 2001; 16(4): 368-73.
43. Mohs RC, Rosen WG, Davis KL. The Alzheimer's Disease Assessment Scale: an instrument for assessing treatment efficacy. *Psychopharmacol Bull*. 1983; 19: 448-50.
44. Rosen WG, Mohs RC, Davis K. A new rating scale for Alzheimer's disease. *Am J Psychiatry*. 1984; 141: 1356-64.
45. Overall JE, Beller SA. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure in an inpatient unit. *J Gerontol*. 1984; 39: 187-93.
46. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychol Rep*. 1962; 10: 799-812.
47. Cohen-Mansfield J, Billig N. Agitated behaviours in the elderly: I. A conceptual review. *J Am Geriatr Soc*. 1986; 34: 711-21.
48. Cohen-Mansfield J. Agitated behaviours in the elderly: II. Preliminary results in the cognitively deteriorated. *J Am Geriatr Soc*. 1986; 34: 722-7.
49. Finkel S, Lyons JS, Anderson RL. Reliability and validity of the Cohen-Mansfield Agitation Inventory in institutionalized elderly. *Int J Geriatr Psychiatry*. 1992; 7: 487-90.
50. Koss E, Weiner M, Ernesto C, Cohen-Mansfield J, Ferris SH, Grundman M, et al. and the Alzheimer's Disease Cooperative Study. Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. *Alzheimer Dis Assoc Disord*. 1997; 11 Suppl 2: S45-50.